Peptide Reality Check

GHK-Cu

Copper peptide · A-tier (Dr. Alex Tatem) · Limited evidence

Best known as a skin-care ingredient. The topical data on collagen and wound healing is real. People also inject it for skin, hair and general repair, but no human trials of that use exist.

Dr. Tatem’s take

A-tier. The topical data is strong and anecdotes are “universally positive”, but “we just don’t have high-quality clinical evidence” for injecting it. In his deep dive he calls injectable safety “probably favorable” and flags Wilson’s disease and liver patients.

In Dr. Tatem’s tier list

History & background

GHK was discovered in 1973 by Loren Pickart, who found that a small peptide in the plasma of young people made aged liver tissue behave more youthfully; its strong affinity for copper (GHK-Cu) was described shortly after.

Through the 1980s–2000s it became a staple cosmetic ingredient for wound healing and anti-aging skin care. Injectable use is a 2020s trend. It was removed from FDA’s Category 2 list in April 2026 and is expected to come before FDA’s compounding advisory committee in a future meeting.

Benefits

Risks

Dosing protocols (informational, labeled by evidence)

Status: Not an approved drug; widely used in cosmetics. Removed from FDA’s Category 2 list in April 2026, but not yet approved for compounding.

Grade and commentary: Dr. Alex Tatem. Watch: GHK-Cu: The Peptide Everyone Is Injecting (Big Mistake?), The Truth About Popular Peptides (What Works, What’s Overhyped) | Peptide Tier List pt.1. Subscribe: @DrAlexTatem.